Amneal Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2018
Filed with the SEC on Mar 1, 2019 and accepted by EDGAR at Mar 1, 2019, 08:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2018-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2018-10-01 to 2018-12-31 | $497.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2018-01-01 to 2018-12-31 | $1.66bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2018-01-01 to 2018-12-31 | $946.6m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2018-10-01 to 2018-12-31 | $193.4m | us-gaap:GrossProfit |
| Gross profit | 12 months2018-01-01 to 2018-12-31 | $716.4m | us-gaap:GrossProfit |
| Research and development | 12 months2018-01-01 to 2018-12-31 | $194.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2018-01-01 to 2018-12-31 | $230.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2018-01-01 to 2018-12-31 | −$19.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2018-01-01 to 2018-12-31 | −$1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2018-10-01 to 2018-12-31 | −$20.3m | us-gaap:ProfitLoss |
| Net income | 12 months2018-01-01 to 2018-12-31 | −$19.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2018-10-01 to 2018-12-31 | −$0.07 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2018-10-01 to 2018-12-31 | −$0.07 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 12 months2018-01-01 to 2018-12-31 | $250.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2018-01-01 to 2018-12-31 | $83.1m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2018-01-01 to 2018-12-31 | $183.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2018-12-31 | $213.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2018-12-31 | $1.29bn | us-gaap:AssetsCurrent |
| Total assets | At period end2018-12-31 | $4.35bn | us-gaap:Assets |
| Current liabilities | At period end2018-12-31 | $553.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2018-12-31 | $2.63bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2018-12-31 | $21.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2018-12-31 | $504.8m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001723128-19-000028. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.